Antitumor activities of some new 1,3,2-oxaza- and 1,3,2-diazaphosphorinanes against K562, MDA-MB-231, and HepG2 cells

[1]  F. Ragab,et al.  Design, Synthesis and Anticancer Evaluation of Novel Tetrahydroquinoline Derivatives Containing Sulfonamide Moiety. , 2010 .

[2]  S. Ghadimi,et al.  Lipophilicity, electronic, steric and topological effects of some phosphoramidates on acethylcholinesterase inhibitory property , 2009 .

[3]  Ali Asghar Ebrahimi Valmoozi,et al.  Structure-activity study of phosphoramido acid esters as acetylcholinesterasf inhibitors , 2008, Journal of enzyme inhibition and medicinal chemistry.

[4]  Z. Shariatinia,et al.  2,3 J (P,X) [X=H, C] coupling constants dependency on the ring size, hybridization and substituents in new diazaphospholes and diazaphosphorinanes, NMR and X-ray crystallography studies , 2007 .

[5]  H. Bijanzadeh,et al.  Conformation of 2-Oxo-2-dimethylamino-1,3,2-λ5- benzoxazaphosphorinane: X-Ray, NMR, and Ab initio Studies , 2007 .

[6]  Z. Shariatinia,et al.  Syntheses and Spectroscopic Studies of Some New Diazaphospholes and Diazaphosphorinanes. Crystal Structure of 4 , 2005 .

[7]  Z. Shariatinia,et al.  Synthesis and Crystal Structure of 5,5-Dimethyl-2-( p-methylanilino)-2-oxo- 1,3,2-diazaphosphorinane , 2005 .

[8]  S. Oikawa,et al.  Oxidative DNA damage induced by a hydroperoxide derivative of cyclophosphamide. , 2004, Free radical biology & medicine.

[9]  T. Owa,et al.  Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. , 2004, Bioorganic & medicinal chemistry letters.

[10]  Longqin Hu,et al.  Nitrobenzocyclophosphamides as potential prodrugs for bioreductive activation: synthesis, stability, enzymatic reduction, and antiproliferative activity in cell culture. , 2003, Bioorganic & medicinal chemistry.

[11]  D. Waxman,et al.  Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. , 2001, Molecular pharmacology.

[12]  D. Waxman,et al.  Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model , 2000, Cancer Gene Therapy.

[13]  F. Fülöp,et al.  Synthesis and conformational study of 1,3,2-oxazaphosphorino[4, 3-a]isoquinolines: a new ring system. , 2000, The Journal of organic chemistry.

[14]  T. Viljanen,et al.  Conformational Study of Some Saturated 2-[Bis(2-chloroethyl)amino]-1,3,2-benzoxazaphosphorinane 2-Oxides. , 1998, The Journal of organic chemistry.

[15]  Michael D. Taylor.  Improved passive oral drug delivery via prodrugs , 1996 .

[16]  D. Waxman,et al.  Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells. , 1995, Biochemical pharmacology.

[17]  W. Setzer,et al.  Anomeric-like substituent effects on the chair-chair conformational equilibrium of the 2-oxo-1,3,2-oxazaphosphorinane ring system , 1991 .

[18]  W. Setzer,et al.  Conformational analysis of 1,3,2-oxazaphospholanes derived from ephedrine and pseudoephedrine , 1989 .

[19]  W. Setzer,et al.  Conformations of saturated six-membered ring phosphorus heterocycles. 2-Aryl-1,3,2-.lambda.5-oxazaphosphorinanes , 1988 .

[20]  G. S. Bajwa,et al.  Conformations of saturated six-membered-ring phosphorus heterocycles related to cyclophosphamide. NMR, x-ray, and infrared studies of 2-methoxy-2-oxo-1,3,2-oxazaphosphorinane and 2-thio-1,3,2-oxazaphosphorinane , 1986 .

[21]  G. Zon,et al.  Synthesis and Antitumor Activity of Cyclophosphamide Analogues. , 1986 .

[22]  G. Zon,et al.  Synthesis and antitumor activity of cyclophosphamide analogues. 4. Preparation, kinetic studies, and anticancer screening of "phenylketophosphamide" and similar compounds related to the cyclophosphamide metabolite aldophosphamide. , 1986, Journal of medicinal chemistry.

[23]  W. Setzer,et al.  CONFORMATIONS OF SATURATED SIX‐MEMBERED PHOSPHORUS HETEROCYCLES. X‐RAY CRYSTALLOGRAPHIC AND PROTON NMR STUDY OF CIS‐2‐OXO‐2‐(DIMETHYLAMINO)‐5‐PHENYL‐1,3,2‐OXAZAPHOSPHORINANE, A CYCLOPHOSPHAMIDE‐LIKE MOLECULE IN A TWIST CONFORMATION , 1984 .

[24]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[25]  A. Camerman,et al.  Activated cyclophosphamide anticancer drugs: molecular structures of cis- and trans-4-hydroperoxyisophosphamides. , 1983, Journal of medicinal chemistry.

[26]  S. Rodenhuis,et al.  Clinical Pharmacokinetics of Cyclophosphamide , 1979, Clinical pharmacokinetics.

[27]  L. Grochow,et al.  Clinical Pharmacokinetics of Cyclophosphamide , 1979, Clinical pharmacokinetics.

[28]  G. Zon,et al.  Synthesis and antitumor activity of cyclophosphamide analogues. 2. Preparation, hydrolytic studies, and anticancer screening of 5-bromocyclophosphamide, 3,5-dehydrocyclophosphamide, and related systems. , 1979, Journal of medicinal chemistry.

[29]  T. L. Lemke,et al.  Phosphorus-nitrogen compounds XVIII: hydrazides and thiosemicarbazides. , 1974, Journal of pharmaceutical sciences.

[30]  A. Camerman,et al.  Cyclophosphamide structure. Molecular structure of 4-ketocyclophosphamide. , 1973, Journal of the American Chemical Society.

[31]  E. Eliel,et al.  Conformational analysis. XVIII. 1,3-Dithianes. Conformational preferences of alkyl substituents and the chair-boat energy difference , 1969 .

[32]  Toshio Fujita,et al.  The Correlation of Biological Activity of Plant Growth Regulators and Chloromycetin Derivatives with Hammett Constants and Partition Coefficients , 1963 .

[33]  H. Tolkmith.  ELECTRON GROUP POLARIZABILITY AND MOLECULAR PROPERTIES OF ORGANOPHOSPHORUS COMPOUNDS * , 1959 .

[34]  B.,et al.  Ficoll Flotation for the Separation of Blood Leukocyte Types , 2005 .

[35]  H. Kozłowski,et al.  Crystal and Molecular Structures of N,N'-Diphenyl-N"-trichloroacetyl- phosphorictriamide and N,N,-Tetraethyl-N"-benzoylphosphorictriamide. The Effect of Various Substituents on the Structural Parameters of the [C(O)N(H)P(O)] Moiety , 1997 .

[36]  W. Setzer,et al.  Conformations of saturated six-membered ring phosphorus heterocycles. X-ray crystallographic and H NMR study of cis-2-oxo-2-(dimethylamino)-3,5-diphenyl-1,3,2-oxozaphosphorinane, a cyclophosphamide-like molecule in a twist conformation , 1984 .

[37]  Norman L. Allinger,et al.  Conformational analysis—CI , 1974 .

[38]  P. Noble,et al.  Ficoll flotation for the separation of blood leukocyte types. , 1968, Blood.